Tattoli Mark Damian 4

What Happened
Mark Damian Tattoli, SVP, General Counsel & Secretary of Core Laboratories (CLB), was granted a derivative award of 33,490 shares on February 12, 2026 (reported on Form 4). The award was recorded at $0.00 per share (a performance-based equity grant rather than an open-market purchase or sale), so there is no immediate cash exchanged — future vesting and number of shares delivered depend on performance metrics.

Key Details

• Transaction date and type: 2026-02-12 — Grant/Award (derivative), reported 2026-02-17. Filing appears timely.
• Reported price: $0.00 per share (award).
• Shares in this grant: 33,490 shares (maximum referenced as 100% of the award; actual vesting can vary).
• Shares owned after transaction: not specified in the excerpt of the filing provided.
• Footnotes / vesting conditions: see below (summarized).
• Filing timeliness: filed Feb 17, 2026; given the Feb 16 holiday, this filing appears within the required SEC window.

Context (simple explanation of the award and vesting)

• The award is a three-year performance-based grant covering the period Jan 1, 2026–Dec 31, 2028. Vesting on Dec 31, 2028 depends on Core Labs’ Return on Invested Capital (ROIC) vs. a Bloomberg Peer Group: 50% vests at the 35th percentile, 100% at the 55th percentile, and up to 175% if at/above the 85th percentile, with straight-line interpolation between tiers.
• An additional adjustment: any portion vesting above 100% (up to the 175% maximum) would be reduced by half if absolute total shareholder return (TSR) over the period is negative.
• The award survives termination for death, disability, termination by the company without cause, or retirement at/after age 62; in those cases vesting (if any) still occurs on Dec 31, 2028.
• Practical takeaway: this is a performance-contingent equity grant, not an immediate purchase or sale; its ultimate value to the insider depends on future company performance.